{"id":"W2767287110","doi":"10.1016/s1470-2045(17)30690-3","title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Quality of life (healthcare); Lung cancer; Discontinuation; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical endpoint; Cancer; Clinical trial; Chemotherapy; Progressive disease; Immunotherapy; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002855164,0.002138372,0.002957077,0.0003910048,0.0005104243,0.001474132,0.001084732,0.002376535,0.0075669],"category_scores_gemma":[0.002402119,0.0007630228,0.003221166,0.0003854364,0.001381525,0.001746939,0.0006539106,0.004506553,0.001095902],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001250053,"about_ca_system_score_gemma":0.0007485439,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008189903,"about_ca_topic_score_gemma":0.00125719,"domain_scores_codex":[0.9988801,0.0006370055,0.00006029296,0.0002023941,0.00006844733,0.0001518315],"domain_scores_gemma":[0.9988974,0.0003950056,0.0002822159,0.00008815774,0.00005776236,0.0002793574],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9865046,0.002073135,0.000351884,0.0004281459,0.0009869047,0.00001908243,0.00003008209,0.0002735856,0.001466115,0.00005803736,0.0004440593,0.007364279],"study_design_scores_gemma":[0.9549946,0.04149203,0.001742815,0.00003340251,0.000682871,0.00002517653,0.00001783925,0.0002574092,0.0002696877,0.0001524594,0.0003188465,0.00001283899],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862618,0.006002225,0.0005784631,0.001033579,0.0005801879,0.001948801,0.001436239,0.00009275971,0.00206598],"genre_scores_gemma":[0.991738,0.001469312,0.0008388167,0.0008044078,0.0002912967,0.001799157,0.001137007,0.0000224855,0.001899521],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0075669,"threshold_uncertainty_score":0.02531379,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1861621644064396,"score_gpt":0.4962273689759054,"score_spread":0.3100652045694658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}